Sales and Marketing

Showing 15 posts of 11524 posts found.

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

August 30, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top 10

Happy Friday! It’s time for another rundown of the top 10 most popular articles with Pharmafile.com readers this week.10. NICE …
roche__tree

Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer

August 30, 2019 Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq

Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …
real_world

Using advanced digital capabilities to unlock hard-to-see HCPs access

August 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing digital pharma, pharma, veeva

Pharmaceutical companies face a ‘digital imperative’ to engage with healthcare professionals through their channel preferences and ensure they are getting …
alexion_solirispackaging

Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder

August 28, 2019 Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris

Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …
thomas-neff

FibroGen rocked by unexpected death of CEO Thomas B Neff

August 27, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, fibrogen, pharma

In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, its Chief Executive Officer and …
https__cdn

NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy

August 27, 2019 Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma

UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …

Four perspectives from life sciences companies on multichannel engagement

August 23, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …
darzalex-product-shot---100mg-vial-2-hr

Japan approves Genmab’s Darzalex in newly diagnosed multiple myeloma

August 22, 2019 Sales and Marketing

Genmab has secured a new approval for its CD38 monoclonal antibody Darzalex (daratumumab), this time in Japan for the treatment …
andrew_dillon

NICE Chief Sir Andrew Dillon to step down in 2020

August 22, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK pharma, UK< pharma

It’s the end of an era at the National Institute of Health and Care Excellence (NICE), the UK watchdog responsible …
gilead-sciences

Gilead challenges Government over patents on preventative HIV drug Truvada

August 22, 2019 Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents

Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …

NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation

August 21, 2019 Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …
astrazeneca-sign

AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure

August 20, 2019 Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga

New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …
fda2outsideweb

FDA greenlights Nebriva’s Xenleta for community-acquired bacterial pneumonia

August 20, 2019 Manufacturing and Production, Sales and Marketing FDA, Nabriva, US, Xenleta, pharma, pneumonia

The FDA has awarded approval in the US to Nebriva Therapeutics’ Xenleta (lefamulin) for the treatment of adult patients with …
733px-reduction_gear

Finding the needle in the haystack of rare disease

August 19, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Genomenon, Rare Genomics Institute, pharma, rare disease

Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory …
The Gateway to Local Adoption Series

Latest content